Cite
HARVARD Citation
van der Lely, A. et al. (2020). Pegvisomant and not somatostatin receptor ligands (SRLs) is first-line medical therapy for acromegaly. European journal of endocrinology. 182 (6), pp. D17-D29. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
van der Lely, A. et al. (2020). Pegvisomant and not somatostatin receptor ligands (SRLs) is first-line medical therapy for acromegaly. European journal of endocrinology. 182 (6), pp. D17-D29. [Online].